Two-step formation of 1H NMR visible mobile lipids during apoptosis of paclitaxel-treated K562 cells

Biochemical Pharmacology

Volumn 65, Issue 8, 2003, Pages 1271-1280

  Brisdelli, Fabrizia ^a   Iorio, Egidio ^b,c   Knijn, Arno ^b   Ferretti, Amalia ^b   Marcheggiani, Donatella ^a   Lenti, Luisa ^c   Strom, Roberto ^c   Podo, Franca ^b   Bozzi, Argante ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; K562 cells; Mobile lipids; Nuclear magnetic resonance spectroscopy; Paclitaxel; Tyrphostin

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CYTOCHROME C; LIPID; MOBILE LIPID; PACLITAXEL; PHOSPHATIDYLSERINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TYRPHOSTIN AG 957; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASPASE; CYTOCHROME C OXIDASE; HYDROGEN; LIPOCORTIN 5;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL DEGENERATION; CELL STRAIN K 562; CELL STRUCTURE; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; MEMBRANE POTENTIAL; MICROTUBULE; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE; CELL MEMBRANE POTENTIAL; DRUG EFFECT; INTRACELLULAR MEMBRANE; KINETICS; METABOLISM; METHODOLOGY; MITOCHONDRION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL CYCLE; ELECTRON TRANSPORT COMPLEX IV; HUMANS; HYDROGEN; INTRACELLULAR MEMBRANES; K562 CELLS; KINETICS; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE POTENTIALS; MITOCHONDRIA; PACLITAXEL;

EID: 0037446263     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00080-7     Document Type: Article

References (51)

1. Blankenberg F.G., Storrs R.W., Naumovski L., Goralski T., Spielman D. Detection of apoptotic cell death by proton magnetic resonance spectroscopy. Blood. 87:1996;1951-1956.
2. Blankenberg F.G., Katsikis P.D., Storrs R.W., Beaulieu C., Spielman D., Chen J.Y., Naumovski L., Tait J.F. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood. 89:1997;3778-3786.
3. 1H NMR-visible mobile lipid domains correlate with cytoplasmic lipid bodies in apoptotic T-lymphoblastoid cells Biochim. Biophys. Acta - Mol Cell Biol. Lipids. 1530:2001;47-66.
4. Al-Saffar N.M.S., Titley J.C., Robertson D., Clarke P.A., Jackson L.E., Leach M.O., Ronen S.M. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br. J. Cancer. 86:2002;963-970.
5. 1H NMR spectroscopy Cell Death Differ. 8:2001;219-224.
6. 1H NMR visible neutral lipids in activated T lymphocytes: relationship to phosphatidylcholine cycle Biochim. Biophys. Acta - Lipids and Lipid Metabol. 1303:1996;215-221.
7. 1H NMR-detectable mobile lipid in stimulated lymphocytes: relationship to cellular activation, the cell cycle, and phosphatidylcholine-specific phospholipase C Biochem. Biophys. Res. Commun. 239:1997;868-874.
8. Mountford CE, Lena CL, Mackinnon WB, Russell P. The use of proton MR in cancer pathology. In: Webbs GA, editor. Annual reports on NMR spectroscopy. New York: Academic Press; 1993. p.173-215.
9. Mountford C.E., Mackinnon W.B., Russell P., Rutter A., Delikatny E.J. Human cancers detected by proton MRS and chemical shift imaging ex vivo. Anticancer Res. 16:1996;1521-1532.
10. May G.L., Wright L.C., Holmes K.T., Williams P.G., Smith I.C., Wright P.E., Fox R.M., Mountford C.E. Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. J. Biol. Chem. 261:1996;3048-3053.
11. 1H magnetic resonance spectroscopy of colon tissue Anticancer Res. 16:1996;1553-1558.
12. 1H -NMR spectroscopy J. Appl. Physiol. 92:2002;2264-2272.
13. 1H NMR-detectable mobile lipid domains in NIH-3T3 fibroblasts Biochim. Biophys. Acta - Mol. Cell Biol. Lipids. 1438:1999;329-348.
14. Mountford C.E., Wright L.C. Organization of lipids in the plasma membranes of malignant and stimulated cells: a new model. Trends Biochem. Sci. 13:1998;172-177.
15. 1H nuclear magnetic resonance correspond to lipid droplets Cancer Res. 57:1997;407-414.
16. Barba I., Cabañas M.E., Arús C. The relationship between nuclear magnetic resonance - visible lipids, lipid droplets and cell proliferation in cultured C6 cells. Cancer Res. 59:1999;1861-1868.
17. 1H NMR visible lipids in the life and death of cells Trends Biochem. Sci. 25:2000;9-14.
18. Strobel T., Kraeft S.K., Chen L.B., Cannistra A. Bax expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for bax during chemotherapy-induced cell death. Cancer Res. 58:1998;4776-4781.
19. Kavallaris M., Burkhart C.A., Horwitz S.B. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer. 80:1999;1020-1025.
20. Glass-Marmor L., Beitner R. Taxol (Paclitaxel) induces a detachment of phosphofructokinase from cytoskeleton of melanoma cells and decreases the levels of glucose 1,6-bisphosphate, fructose 1,6-bisphosphate and ATP. Eur. J. Pharmacol. 370:1999;195-199.
21. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death. Cancer. 88:2000;2619-2628.
22. Bedi A., Barber J.P., Bedi G.C., el-Deiry W.S., Sidranski D., Vala M.S., Akhtar A.J., Hilton J., Jones R.J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 86:1995;1148-1158.
23. Cortez D., Kadlec L., Pendergast A.M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell Biol. 15:1995;5531-5541.
24. Riordan F.A., Bravery C.A., Mengubas K., Ray N., Borthwick N.J., Akbar A.N., Hart S.M., Hoffbrand A.V., Metha A.B., Wickremasinghe R.G. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of BCR/ABL-positive leukemia cells. Oncogene. 16:1998;1533-1542.
25. Beran M., Cao X., Estrov Z., Jeha S., Jin G., O'Brien S., Talpaz M., Arlinghaus R.B., Lydon N.B., Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4:1998;1661-1672.
26. Sun X., Layton J.E., Elefanty A., Lieschke G.J. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and ST1571. Blood. 97:2001;2008-2015.
27. McGahon A.J., Martin S.J., Bissonnette R.P., Mahboubi A., Shi Y., Mogil R.J., Nishioka W.K., Green D.R. The end of the (cell) line: methods for the study of apoptosis in vitro. Methods Cell Biol. 46:1995;153-185.
28. Nicoletti I., Migliorati G., Pagliacci F., Grignani C., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 39:1991;271-279.
29. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. NewYork: Cold Spring Harbor; 1989.
30. Cossarizza A., Baccarani-Contri M., Kalashnikova G., Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazolo-carbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun. 97:1993;40-45.
31. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
32. Gangemi R.M., Santamaria B., Bargellesi A., Cosulich E., Fabbi M. Late apoptotic effects of taxanes on K562 erythroleukemia cells: apoptosis is delayed upstream of caspase-3 activation. Int. J. Cancer. 85:2000;527-533.
33. Chadebech P., Brichese L., Baldin V., Vidal S., Valette A. Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. 262:1999;823-827.
34. Murphy D.J., Vance J. Mechanisms of lipid-body formation. Trends Biochem. Sci. 24:1999;109-115.
35. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis Nat. Med. 5:1999;1323-1327.
36. Kroemer G., Zamzami N., Susin S.A. Mitochondrial control of apoptosis. Immunol. Today. 18:1997;44-51.
37. Lieu C.H., Chang Y.N., Lai Y.K. Dual cytotoxic mechanism of submicromolar Taxol on human leukemia HL-60 cells. Biochem. Pharmacol. 53:1997;1587-1596.
38. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem. Pharmacol. 57:1999;1215-1221.
39. Sena G., Onado C., Cappella P., Montalenti F., Ubezio P. Measuring the complexity of cell-cycle arrest and killing of drugs: kinetics of phase-specific effects induced by Taxol. Cytometry. 37:1999;113-124.
40. Ling Y.H., Tornos C., Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M-phase events and not a determinant of apoptosis. J. Biol. Chem. 273:1998;18984-18991.
41. Cifone M.G., Roncaioli P., De Maria R., Camarda G., Santoni A., Ruberti G., Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14:1995;5859-5868.
42. Senchenkov A., Litvak D.A., Cabot M.C. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93:2001;347-357.
43. Scaffidi C., Schmitz I., Zha J., Korsmeyer S.J., Krammer P.H., Peter M.E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274:1999;22532-22538.
44. De Maria R., Lenti L., Malisan F., d'Agostino F., Tomassini B., Zeuner A., Rippo M.R., Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 277:1997;1652-1655.
45. Morjani H., Aouali N., Belhoussine R., Veldman R.J., Levade T., Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int. J. Cancer. 94:2001;157-165.
46. Ferretti A, Knijn A, Raggi C, Sargiacomo M. High-resolution proton NMR measures mobile lipids associated with Triton-resistant membrane domains in haematopoietic K652 cells lacking or expressing caveolin-1. Eur Biophys J 2003, in press.
47. Delikatny E.J., Couper W.A., Brammah S., Sathasivan N., Rideout D.C. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res. 62:2002;1394-1400.
48. Martinou J.C., Desagher S., Antonsson B. Cytochrome c release from mitochondria: all or nothing. Nat. Cell Biol. 2:2000;E41-E43.
49. Von Ahsen O., Waterhouse N.J., Kuwana T., Newmeyer D.D., Green D.R. The "harmless" release of cytochrome c. Cell Death Differ. 7:2000;1192-1199.
50. 2 in tumor necrosis factor-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5073-5077.
51. De Valck D., Vercammen D., Fiers W., Beyaert R. Differential activation of phospholipases during necrosis and apoptosis: a comparative study using tumor necrosis factor and anti-Fas antibodies. J. Cell Biochem. 71:1997;392-399.